aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. (ATYR)
Company Research
Source: GlobeNewswire
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors approved on March 21, 2025 an aggregate of three grants to three employees of nonstatutory stock options to purchase an aggregate of 43,800 shares of aTyr’s common stock with a weighted-average exercise price of $3.69 per share, which is equal to the weighted-average closing price of aTyr’s common stock on the Nasdaq Capital Market on the effective dates of the grants. These stock awards we
Read more
Impact Snapshot
Event Time:
ATYR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATYR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATYR alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATYR
News
- aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod FranchiseGlobeNewswire
- aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating [Seeking Alpha]Seeking Alpha
- Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate UpdateGlobeNewswire
ATYR
Earnings
- 3/13/25 - Beat
ATYR
Sec Filings
- 3/19/25 - Form ARS
- 3/19/25 - Form DEFA14A
- 3/19/25 - Form DEF
- ATYR's page on the SEC website